Dr. Ronald A Lehman, M.D.

Claim this profile

Columbia University Irving Medical Center

Studies Spinal Injury
Studies Scoliosis
2 reported clinical trials
7 drugs studied

Affiliated Hospitals

Image of trial facility.

Columbia University Irving Medical Center

Clinical Trials Ronald A Lehman, M.D. is currently running

Image of trial facility.

Tranexamic Acid

for Spinal Injury

This study is designed to evaluate the efficacy of topical tranexamic acid to reduce perioperative blood loss, reduction in postoperative drain output and allogenic transfusion requirements. The proposed study will be a prospective, randomized, double-blind (subject, surgeons, investigators, research coordinators) placebo-controlled study. Patients requiring posterior spinal fusion will be enrolled for this study. Furthermore, patients undergoing elective complex deformity surgery will also be enrolled. Both populations of patients will be randomized into two groups. Group I will receive standard of care operative fixation with topical tranexamic acid intervention (test); Group II will receive standard of care operative fixation with normal saline (placebo) intervention. This study will have a 2-year follow-up and will consist of three periods: screening/enrollment phase up to 21 days from the day of injury to the day of randomization and operative intervention, an inpatient data collection period for 4 days postoperative, and then a follow-up period for 2-years postoperative (visits occurring at 16 weeks, 1 year, and 2 year) time points.

Recruiting

0 awards

Phase 2 & 3

Image of trial facility.

Spinal Cord Stimulation

for Spinal Cord Injury

Spinal cord associative plasticity (SCAP) is a combined cortical and spinal electrical stimulation technique developed to induce recovery of arm and hand function in spinal cord injury. The proposed study will advance understanding of SCAP, which is critical to its effective translation to human therapy. The purpose of the study is to: 1. Determine whether signaling through the spinal cord to the muscles can be strengthened by electrical stimulation. 2. Improve our understanding of the spinal cord and how it produces movement. 3. Determine whether spinal surgery to relieve pressure on the spinal cord can improve its function. Aim 1 is designed to advance mechanistic understanding of spinal cord associative plasticity (SCAP). Aim 2 will determine whether SCAP increases spinal cord excitability after the period of repetitive pairing. In rats, SCAP augments muscle activation for hours after just 5 minutes of paired stimuli. Whereas Aims 1 and 2 focused on the effects of paired stimulation in the context of uninjured spinal cord, Aim 3 assesses whether paired stimulation can be effective across injured cord segments. Aim 3 will incorporate the experiments from Aim 1 and 2 but in people with SCI, either traumatic or pre-operative patients with myelopathy in non-invasive experiments, or targeting myelopathic segments in intraoperative segments.

Recruiting

1 award

Phase < 1

9 criteria

More about Ronald A Lehman, M.D.

Clinical Trial Related

5 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical Trials

Treatments Ronald A Lehman, M.D. has experience with

  • Placebo
  • Tranexamic Acid
  • Intraoperative Pairing Of Cortical And Spinal Stimulation
  • Intraoperative Repeated Pairing Of Cortical And Spinal Stimulation (SCAP)
  • Intraoperative Repeated Pairing Of Cortical And Spinal Stimulation (SCAP) At Or Below Myelopathic Region
  • Non-invasive Pairing Of Cortical And Spinal Stimulation

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Ronald A Lehman, M.D. specialize in?

Is Ronald A Lehman, M.D. currently recruiting for clinical trials?

Are there any treatments that Ronald A Lehman, M.D. has studied deeply?

What is the best way to schedule an appointment with Ronald A Lehman, M.D.?

What is the office address of Ronald A Lehman, M.D.?

Is there any support for travel costs?